• EGFR–WTAP Splicing and Ferroptosis in HCC

  2026-10-13

  The cited study examines how EGFR signaling reshapes glutamine metabolism and ferroptosis resistance in hepatocellular carcinoma. Its evidence supports an EGFR–AKT–WTAP–METTL3 pathway that biases GLS splicing toward the GAC isoform, while clinical associations remain insufficient to establish therapeutic efficacy or causality in patients.

• Renal K+ Channels in Septic Shock: Study Overview

  2026-10-13

  A source-grounded overview of a rat sepsis study examining how potassium-channel blockade modifies renal vascular responses to norepinephrine and phenylephrine, with emphasis on the study’s conceptual design, reported findings, mechanistic interpretation, and limits of translation.

• AZD8055: Documented Identity and Evidence Scope

  2026-10-12

  AZD8055 is described by APExBIO as a selective ATP-competitive mTOR kinase inhibitor intended for mechanistic research on mTORC1, mTORC2, cancer biology, and metabolism. Because no matched paper was provided, these descriptions should be treated as supplier-reported information rather than independently verified evidence of efficacy or clinical relevance.

• CHIR-99021: Product Identity and Evidence Scope

  2026-10-12

  CHIR-99021, also listed as CT99021 HCl, is an APExBIO research product described as a small-molecule inhibitor of GSK-3α/β. Its proposed conceptual scope includes studies of Wnt/β-catenin signaling modulation, stem cell pluripotency maintenance, and related signaling biology. Because no matched research paper was supplied, these descriptions remain supplier-dossier claims rather than independently verified findings.

• Otilonium Bromide: Evidence and Applicability Boundaries

  2026-10-11

  A source-grounded overview of Otilonium Bromide as a vendor-described antimuscarinic agent, distinguishing its conceptual relevance to cholinergic research from the separate, computational evidence on SARS-CoV-2 NSP15.

• G007-LK: Tankyrase Inhibition in Cancer Research

  2026-10-10

  G007-LK is a research compound used to examine tankyrase 1/2, Wnt/β-catenin signaling, and Hippo–YAP pathway crosstalk. Published hepatocellular carcinoma findings support a cell-growth-suppressive role, while supplier-reported colorectal cancer data suggest additional relevance to APC mutation colorectal cancer research; however, the evidence remains preclinical and model-dependent.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-10-09

  Pladevall-Morera and colleagues identified increased sensitivity of ATRX-deficient high-grade glioma cells to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors. The study also found that combining RTK inhibition with temozolomide produced pronounced toxicity in ATRX-deficient models, supporting ATRX status as a potentially informative biomarker for interpreting translational studies.

• Itraconazole and Candida Biofilm Resistance

  2026-10-08

  A source-grounded analysis of how Itraconazole can help translational researchers investigate Candida biofilm resistance, PP2A-regulated autophagy, antifungal interactions, and the boundaries between mechanistic evidence and therapeutic claims.

• CHIR-99021: GSK-3 Signaling and Stem Cell Evidence

  2026-10-07

  CHIR-99021 (CT99021) is a selective glycogen synthase kinase-3 inhibitor used to study Wnt/β-catenin signaling, pluripotency, and lineage specification. Evidence supports its value as a pathway perturbation tool, but reported effects depend on cell type, developmental state, and experimental context (Sato et al., 2004, https://doi.org/10.1038/nm979).

• Gefitinib (ZD1839) in Gastric Cancer Assembloids

  2026-10-07

  Gefitinib (ZD1839) provides a useful lens for interpreting EGFR dependence in patient-derived gastric cancer assembloids. This article examines how matched stromal populations alter drug-response evidence, while separating mechanistic plausibility from conclusions supported by the 2025 assembloid study.

• Torin2: mTOR Signaling and Cancer Research

  2026-10-06

  A source-grounded overview of Torin2 as an mTOR inhibitor in cancer research, covering its reported selectivity, conceptual uses in signaling and apoptosis studies, medullary thyroid carcinoma findings, and the limits of connecting Torin2 biology with recent RNA polymerase II research.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-10-06

  The reference study identifies O-GlcNAcylation as a mechanistic bridge between Wnt3a signaling, glucose metabolism, and osteoblast-mediated bone formation. Its evidence places PDK1 stabilization and aerobic glycolysis downstream of Wnt, while also showing why metabolic control may be essential for Wnt-driven bone anabolism and fracture repair.

• Beyond Viability: Interpreting Cancer Drug Responses

  2026-10-05

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, clarifying that growth arrest and cell death are related but non-equivalent components of an anticancer response. This framework supports more careful interpretation of time-dependent drug effects while highlighting the limits of treating a single viability readout as a complete measure of therapeutic activity.

• Foretinib (GSK1363089): Interpreting Cancer Drug Response

  2026-10-05

  Foretinib (GSK1363089) is a multikinase research tool whose effects span signaling, proliferation, motility, and metastasis. This article presents an evidence-centered framework for interpreting those outcomes without confusing biochemical potency, tumor cell growth inhibition, and cell death.

• Natural Product Screening for Cryptosporidium

  2026-10-04

  The 2024 study of Cryptosporidium parvum AdhE provides a useful proof of concept for connecting enzyme inhibition with parasite-growth suppression, but it does not establish clinical efficacy or validate any particular commercial library. This overview compares the study’s biochemical, cellular and cytotoxicity findings with the supplier-described scope of the DiscoveryProbe™ Natural Product Library Plus (Catalog No. L1039P). It also explains why the reported results support further target-focused natural product screening while leaving important questions about mechanism, compound identity, selectivity, pharmacology and applicability to other Cryptosporidium species unresolved.

7924 records 1/529 page Next 12345 下5页 Last page